Profusa Secures $13.2M in Series B Financing

profusaProfusa, Inc., a South San Francisco, CA-based developer of biologically integrated sensors that allow individuals to monitor their unique body chemistry, secured $13.2m in Series B financing.

The round was led by 3E Bioventures, with participation from Asset Management Ventures, Qihoo 360, and other Series A investors. In conjunction with the funding, Karen Liu, Ph.D., Managing Partner of 3E Bioventures, joined Profusa’s board along with Joan Braddi, Vice President of Global Product Partnerships at Google, Inc., a subsidiary of Alphabet Inc.

The company intends to use the funds for the development and com­mercialization of its technology.

Founded in 2009 and led by Ben Hwang, Ph.D., chairman and CEO, Profusa provides an internal biosensor technology for long-term, continuous monitoring of body chemistry for improving personal health and managing disease. The company’s first product, the Lumee Oxygen Sensing System™, is slated to be available in Europe in early 2016 for the measurement of tissue-oxygen perfusion in the clinical management of chronic wounds.

Profusa has raised more than $30m in funding since its creation.



Join the discussion